Skip to main content

A Closer Look at Lung Cancer Research: From Discovery to Patient Care

Nov 19, 2026, 10:45 AM
At the University of Cincinnati Cancer Center, researchers are approaching the disease from multiple perspectives — developing new imaging tools, investigating the immune system's role in cancer development and identifying ways to improve access to screening and treatment.

November is National Lung Cancer Awareness Month, a time to raise awareness of lung cancer and highlight the research advancing prevention, early detection and treatment. At the University of Cincinnati Cancer Center, researchers are approaching the disease from multiple perspectives — developing new imaging tools, investigating the immune system's role in cancer development and identifying ways to improve access to screening and treatment.

In the United States, lung cancer remains the leading cause of cancer-related death among both men and women. According to the NIH’s National Cancer Institute, an estimated 229,410 people are expected to be diagnosed with lung cancer, and approximately 124,990 are expected to die from the disease. Although cigarette smoking is the most common cause of lung cancer, other factors, including secondhand smoke, radon, occupational exposures and inherited risk, can also contribute to its development. Lung cancer can also occur in people who have never smoked.

There are two main types of lung cancer: non-small cell lung cancer (NSCLC), which accounts for over 85% of cases, and small cell lung cancer (SCLC), a less common but typically more aggressive form of the disease. Advances in targeted therapies, immunotherapy and surgical techniques have improved outcomes, but early detection remains a significant challenge. Lung cancer screening with low-dose computed tomography (CT) is recommended annually for eligible adults ages 50 to 80 with a 20-pack-year smoking history who currently smoke or have quit within the past 15 years. However, many eligible individuals do not receive screening, and too many patients are diagnosed after their cancer has spread.

Researchers at the Cancer Center are working to address these challenges across the lung cancer care continuum, from identifying suspicious findings on medical imaging to understanding biological risk factors and ensuring patients can access timely, effective treatment.

Improving Early Detection Through Imaging and Artificial Intelligence

Although primary lung cancer is rare in children, the lungs are among the most common sites for cancer to spread in both pediatric and adult patients. When cancer spreads to the lungs, it often appears as small growths called pulmonary nodules. Identifying these nodules is important for determining the extent of disease, planning treatment and monitoring patients over time.

However, not every pulmonary nodule is cancerous, and distinguishing malignant nodules from benign findings can be difficult using medical imaging alone.

Aki Tanimoto, MD, an associate member in the Experimental Diagnostics & Therapeutics Research Program at the Cancer Center, Andrew Trout, MD, a member in the Experimental Diagnostics & Therapeutics Research Program at the Cancer Center, and Jonathan Dillman, MD, MSc, medical director of the Imaging Research Center at Cincinnati Children’s, are investigating how artificial intelligence (AI) can help radiologists identify and characterize pulmonary nodules in children. Working with Russell Hardie, PhD, a professor of electrical and computer engineering at the University of Dayton, the team is studying computer-aided detection (CAD) systems designed to identify suspicious findings on CT scans.

Although CAD systems have been developed to help detect pulmonary nodules in adults, the team found that systems trained using adult imaging data do not perform as well when applied to pediatric patients, missing more nodules in children. Currently, there are no FDA-approved CAD systems specifically designed for pediatric use.

Recently published in the Journal of Medical Imaging, the team demonstrated that adult-trained CAD systems can be fine-tuned using pediatric imaging data to improve nodule detection in children.

“Pediatric medical imaging data is much less available than adult data, and adult-trained CAD algorithms exhibit lower sensitivity in children,” Tanimoto explained. “The study also shows that adult models can be effectively adapted for pediatric use, providing a practical, efficient pathway to develop pediatric-specific diagnostic tools without needing to build them entirely from scratch.”

Headshot image of Aki Tanimoto, MD
 

Aki Tanimoto, MD
Associate Member, Experimental Diagnostics & Therapeutics Research Program
University of Cincinnati Cancer Center

Headshot image of Andrew Trout, MD
 

Andrew Trout, MD
Member, Experimental Diagnostics & Therapeutics Research Program
University of Cincinnati Cancer Center

The team is also exploring radiomics, an emerging approach that extracts detailed imaging characteristics — some of which may not be readily visible to the human eye — to help predict whether a pulmonary nodule is malignant. While radiomics is an active area of research in adult lung cancer, less work has been done to characterize metastatic and pediatric lung nodules.

“The ultimate goal of this work is clinical integration of the AI tools to improve patient outcomes through early and accurate detection of potentially malignant pulmonary nodules,” Tanimoto said.

Beyond improving detection, AI tools may also help streamline radiology workflows and reduce the cognitive burden on radiologists. These benefits could be particularly meaningful in pediatric radiology, where shortages of specialized radiologists and increasing imaging volumes create additional demands on clinical teams.

Looking ahead, the researchers are working to develop a publicly available pediatric pulmonary nodule database to support additional research and the development of pediatric-specific algorithms for both detection and characterization. Their long-term goal is to improve the identification of lung nodules in children while helping clinicians more accurately determine which findings may represent cancer.

Understanding the Immune System's Role in Lung Cancer

While imaging research focuses on identifying suspicious findings, other University of Cincinnati Cancer Center investigators are studying the biological changes that may contribute to lung cancer development long before a tumor is detected.

Michael Borchers, PhD, a member of the Signaling & Metabolic Pathways Research Program at the Cancer Center, studies how chronic lung injury affects the immune system's ability to recognize and eliminate abnormal cells.

Lung cancer and chronic obstructive pulmonary disease (COPD) frequently occur together. Smoking is a major risk factor for both conditions, and approximately half of people diagnosed with lung cancer also have COPD. However, researchers still cannot reliably identify which individuals who smoke or have COPD are most likely to develop lung cancer.

“The central challenge is that we cannot yet tell which smokers and which COPD patients will go on to develop cancer,” Borchers explained. “So, we are left screening and intervening late rather than identifying the people whose lungs are already losing the ability to control abnormal cells.”

Headshot image of Michael Borchers, PhD
 

Michael Borchers, PhD
Member, Signaling & Metabolic Pathways Research Program
University of Cincinnati Cancer Center

One area of Borchers' research focuses on natural killer (NK) cells, a type of immune cell that helps identify and eliminate stressed, damaged or abnormal cells. Unlike some other immune responses that require time to develop, NK cells are part of the body's innate immune system and can recognize potential threats early.

Although immunotherapy has transformed lung cancer treatment, much of the research has focused on T cells, and many patients do not respond to these therapies. Borchers is investigating whether changes in NK cell function could help explain why some people develop cancer and whether those changes could eventually be measured or reversed.

In a recent study published in the Journal of Clinical Medicine, Borchers and his colleagues examined blood samples from 586 current, former and never smokers, including individuals with and without lung cancer.

The researchers found that higher circulating levels of a protein called sMICA*008 were associated with smoking, lung cancer and, among participants without cancer, the presence of COPD. The protein is released by stressed and transformed cells and can interfere with NK cell activity, providing a potential mechanism through which abnormal cells may evade immune surveillance.

These findings suggest that sMICA*008 could eventually serve as a blood-based biomarker to help identify individuals with changes associated with lung cancer or chronic lung disease. However, because the study examined associations at a single point in time, additional research is needed to determine whether these levels can predict disease development or progression.

Borchers sees this work as part of a broader effort to understand and potentially restore the immune system's ability to recognize cancer.

“My group is investigating how chronic inhalational injury degrades immune surveillance in the lung, if that loss can be measured in a blood sample and if it can be restored,” he said.

His research also connects with other work at the Cancer Center. In collaboration with Trisha Wise-Draper, MD, deputy director of the IU Melvin and Bren Simon Comprehensive Cancer Center, researchers are investigating NK cell activity in head and neck cancer. A phase II clinical trial combining metformin with pembrolizumab, an immunotherapy drug, examined whether the combination could influence NK cell maturation and activity in patients with metastatic head and neck cancer.

Borchers also studies rare lung diseases, including pulmonary Langerhans cell histiocytosis and lymphangioleiomyomatosis, which provide additional opportunities to investigate the relationship between abnormal cell growth and immune surveillance.

Looking ahead, Borchers is particularly interested in whether changes in circulating sMICA levels track with disease progression over time.

“That is the step that would turn an association into a usable clinical tool,” he said.

If future studies validate these findings, blood-based biomarkers could help identify individuals who may benefit from closer monitoring or earlier screening. More broadly, understanding how to restore NK cell function could open new possibilities for immunotherapy, including for patients who do not currently respond to existing treatments.

Improving Access to Screening and Potentially Curative Treatment

Alongside research focused on imaging and cancer biology, University of Cincinnati Cancer Center investigators are examining another important part of improving lung cancer outcomes: ensuring patients can access screening and appropriate treatment when they need it.

Robert Van Haren, MD, MSPH, associate member of the Population Sciences & Prevention Research Program at the Cancer Center, studies barriers to lung cancer screening, delays in treatment and opportunities to improve outcomes after surgery.

“Lung cancer is often curable when detected early,” Van Haren said. “Unfortunately, many patients are diagnosed after the cancer has already spread.”

Headshot image of Robert Van Haren, MD, MSPH
 

Robert Van Haren, MD, MSPH
Associate Member, Population Sciences & Prevention Research Program
University of Cincinnati Cancer Center

Although advances in immunotherapy, targeted treatments and minimally invasive surgical techniques have expanded treatment options, not all patients benefit equally. Many eligible individuals do not participate in recommended lung cancer screening, while others experience delays or barriers to receiving potentially curative treatment.

Van Haren's research examines how healthcare practices and policies may unintentionally contribute to these barriers. One example is the requirement that patients stop smoking before undergoing lung cancer surgery.

Smoking increases the risk of postoperative complications, and smoking cessation remains an important part of improving patients' health. However, requiring patients to quit before surgery may delay treatment or prevent some from receiving surgery altogether.

In two recent studies, Van Haren and his colleagues examined whether smoking status alone should influence a patient's eligibility for potentially curative lung cancer surgery.

The first study, published in Annals of Thoracic Surgery Short Reports, analyzed 862 patients from the National Lung Screening Trial. Researchers found that patients who continued smoking experienced higher rates of moderate or major postoperative complications, but there was no statistically significant difference in mortality compared with patients who had stopped smoking.

A subsequent study, published in the Journal of the American College of Surgeons, examined more than 85,000 patients who underwent lung cancer resection using data from the Society of Thoracic Surgeons General Thoracic Surgery Database. Current smokers had slightly higher rates of postoperative pulmonary complications than nonsmokers — 34.6% compared with 30.5% — but mortality was identical at 1% in both groups.

Together, these findings suggest that while smoking cessation should be encouraged, smoking status alone should not determine whether a patient is offered potentially curative surgery.

“We should instead evaluate each patient's individual risk factors and work to optimize their health without creating unnecessary barriers to treatment,” Van Haren explained.

This research is part of a broader effort to understand how patients move through the lung cancer care continuum, including why eligible individuals do not undergo screening, what contributes to delays in treatment and how communication between patients and physicians influences care decisions.

Van Haren emphasized that improving access to existing treatments is just as important as developing new ones.

“Discovering new treatments is essential, but those discoveries can only benefit patients if they are diagnosed early enough and can access appropriate care,” he said.

In the Cancer Center’s ten-county catchment area, where lung cancer continues to have a significant impact on the community, improving screening participation and reducing barriers to treatment could help more patients benefit from advances in care. Van Haren and his colleagues are working with primary care providers, community organizations and healthcare partners to increase awareness of screening and help patients navigate the healthcare system from diagnosis through treatment.

Connecting Research Discoveries to Patient Care

Together, these research efforts reflect the breadth of lung cancer research happening at the University of Cincinnati Cancer Center. From developing pediatric-specific imaging tools to identifying potential blood-based biomarkers and evaluating barriers to surgical care, investigators are addressing challenges at different points along the cancer continuum.

Each project also highlights an important opportunity to improve patient outcomes: detecting suspicious findings more accurately, identifying individuals who may be at greater risk, understanding the biological mechanisms that contribute to cancer and ensuring that patients have access to effective treatment.

As lung cancer research continues to evolve nationally, the Cancer Center's work contributes to a broader effort to make advances in cancer research meaningful in clinical practice. By combining expertise in radiology, engineering, immunology, surgery and population health, researchers are working to address both the biological challenges of lung cancer and the practical barriers that affect patient care.

During National Lung Cancer Awareness Month, these efforts underscore the importance of continued research across the entire lung cancer care continuum. Whether through earlier detection, improved risk assessment or more equitable access to treatment, the goal remains the same: helping more patients receive the right care at the right time and improving outcomes for individuals and communities affected by lung cancer.

Contact Us

University of Cincinnati
Cancer Center

231 Albert Sabin Way, Suite 2005
Cincinnati, OH 45267
Phone: 513-558-2177
Fax: 513-558-2666